Войти в систему Зарегистрироваться бесплатно

Hutchison China MediTech Цель на 1 год

Что обозначает Цель на 1 год в Hutchison China MediTech?

Цель на 1 год Hutchison China MediTech Ltd. является GBX316 +24.42%

Какое определение для Цель на 1 год?

Цель на 1 год - это прогнозируемая цена акций через год.

One year target is an estimate of a stock price for a point in time equal to a year from the current date. The price level most often reflects the collective opinion of different analysts on where the stock will be trading a year from now. For an analyst to identify an individual estimate, they have to project what a company’s business will look like in a year, typically focusing on revenue and other significant factors. They also consider the willingness of investors to pay a certain price. While the average or median recommendation may be predictive and reflect the actual future value, the results are usually not extremely successful.

Цель на 1 год компаний в Health Care сектор на LSE по сравнению с Hutchison China MediTech

Что делает Hutchison China MediTech?

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.

Компании с цель на 1 год похож на Hutchison China MediTech